Esophageal and Gastroesophageal Junction Carcinoma — knowledge graph · CancerIndex

Knowledge graph · Cancer

Esophageal and Gastroesophageal Junction Carcinoma

subtype

Identifier: CI-CAN-00002608
Entity page: /cancer/esophageal-and-gastroesophageal-junction-carcinoma ↗
Edges: 1,922

Neighbours: 15 genes20 drugs10 trials
Drawn: 45 of 45 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Esophageal and Gastroesophageal Junction Carcinoma approved for …APPROVED_FORderived25 of 25show fewer
← approved for	Fluorouracilsmall molecule FDA (US) · approved · 2026-02-20 · Gastric Adenocarcinoma	—	approved	Gastric Adenocarcinoma	1	Regulatory	openfda	graph →
← approved for

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

ERBB2 Amplification TrastuzumabFDA US 1998-09-2517 active / 30 trials
Curatedlevel Asensitivity· support 2civicObservedcohort frequency not yet available for ERBB2 in this cancerRegulatoryapproved for Gastroesophageal Junction Adenocarcinoma (3 approval records)context: Gastric Adenocarcinoma
TP53 Mutation Chemotherapy15 active / 23 trials
Curatedlevel Bsensitivity· support 1civicObservedTP53 altered in 60% (309 / 518 cases, largest of 19 cohorts)no approval record in this cancercontext: Gastric Adenocarcinoma
TP53 Wildtype Chemotherapy15 active / 23 trials
Curatedlevel Bsensitivity· support 1civicObservedTP53 altered in 60% (309 / 518 cases, largest of 19 cohorts)no approval record in this cancercontext: Esophageal Carcinoma
AURKA EXPRESSION Cisplatin28 active / 80 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for AURKA in this cancerno approval record in this cancercontext: Esophageal Squamous Cell Carcinoma
AURKA EXPRESSION FluorouracilFDA US 2026-02-2041 active / 98 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for AURKA in this cancerRegulatoryapproved for Gastric Adenocarcinomacontext: Esophageal Squamous Cell Carcinoma
AURKA EXPRESSION Radiation Therapy0 active / 0 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for AURKA in this cancerno approval record in this cancercontext: Esophageal Squamous Cell Carcinoma
ERBB2 Amplification Lapatinib0 active / 4 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: Gastric Adenocarcinoma
MET Amplification Onartuzumab0 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for MET in this cancerno approval record in this cancercontext: Gastric Adenocarcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Esophageal and Gastroesophageal Junction Carcinoma altered in cohorts of …ALTERED_INderived15 of 444show all (up to 200)
← altered in cohorts of	CDKN2B 133 / 185 cases (72 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	EFR3A 133 / 185 cases (72 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	HHLA1 132 / 185 cases (71 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	KHDRBS3 132 / 185 cases (71 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	LRRC6 132 / 185 cases (71 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	NDRG1 132 / 185 cases (71 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	OC90 132 / 185 cases (71 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	SLA 132 / 185 cases (71 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ZFAT 132 / 185 cases (71 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PHF20L1 131 / 185 cases (71 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ST3GAL1 131 / 185 cases (71 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TMEM71 131 / 185 cases (71 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ACTRT3 130 / 185 cases (70 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	BCHE 130 / 185 cases (70 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	LRRC31 130 / 185 cases (70 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →

Esophageal and Gastroesophageal Junction Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 144show all (up to 200)
→ investigated in trials for	Fluorouracilsmall molecule 98 trials (41 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	98	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 96 trials (45 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	96	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 96 trials (44 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	96	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 80 trials (28 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	80	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 76 trials (26 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	76	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 66 trials (32 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	66	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 52 trials (20 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	52	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 48 trials (15 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	48	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 48 trials (22 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	48	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 38 trials (20 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	38	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 36 trials (19 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	36	Observed	clinicaltrials	graph →
→ investigated in trials for	Tislelizumabmonoclonal antibody 35 trials (21 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	35	Observed	clinicaltrials	graph →
→ investigated in trials for	Trastuzumabmonoclonal antibody 30 trials (17 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	30	Observed	clinicaltrials	graph →
→ investigated in trials for	Ramucirumabmonoclonal antibody 27 trials (10 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Toripalimabmonoclonal antibody 27 trials (14 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	27	Observed	clinicaltrials	graph →

Esophageal and Gastroesophageal Junction Carcinoma studied in …STUDIED_INderived10 of 1,309show all (up to 200)
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)	—	—	Esophageal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06203600Phase 2/Phase 3 · recruiting Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · condition mapped CURATED_BROADER · 1,309 trials mapped (550 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07212491enrolling by invitation Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07529808Phase 1/Phase 2 · recruiting Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)	—	—	Gastric Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07603375Phase 2 · recruiting Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03030404completed Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer · condition mapped ALIAS · 1,309 trials mapped (550 active)	—	—	Hereditary Gastric Diffuse Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05965999recruiting Lucid Registry Study · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07277413Phase 1 · recruiting A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)	—	—	Gastric Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07392892Phase 2/Phase 3 · recruiting Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07733180Phase 2 · recruiting A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC · condition mapped CURATED_BROADER · 1,309 trials mapped (550 active)	—	—	Esophageal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →